Italian Pharma Manufacturers: Export Pipeline 2026

Italy exported EUR 69.2 billion of pharmaceuticals in 2025, a 28.5% rise on 2024 and the largest single contribution to Italian manufacturing export growth. The sales machinery behind that number is thinner than the number suggests. Most Italian pharmaceutical manufacturers below multinational scale still build their export pipeline from two or three fairs a year, a handful of distributors, and relationships formed a decade ago.

That was survivable while the buyer side sat still. It is not sitting still. The European Union is finishing legislation that puts the location of a medicine’s active substance into procurement decisions, and the formulators who make those decisions are rebuilding their supplier files now. Italian plants hold the strongest position in Europe to win that work, and almost no route to the people doing the rebuilding.

How big is Italy’s pharmaceutical export business?

Farmindustria’s 2026 facts and figures briefing puts production at EUR 74 billion in 2025 and exports at EUR 69.2 billion. Exports have grown 248% over ten years against an EU average of 148%. Pharmaceuticals now account for 11.3% of everything Italian manufacturing sells abroad, and the sector carries an EUR 11.4 billion foreign trade surplus.

The industrial base behind that is roughly 200 companies running more than 130 production sites and employing 72,200 people. Investment reached EUR 4.4 billion in 2025, split between EUR 1.9 billion in high-technology plant and EUR 2.5 billion in research and development. Capacity has been added steadily for five years.

Ownership decides who has to sell it. Agenzia ICE counts around 283 pharmaceutical enterprises in Italy, 220 of them producing finished medicines, with 43% under Italian capital and 57% under foreign capital. A plant inside a multinational group receives its volumes from the group. The Italian-owned mid-caps have to go out and find theirs.

Which buyers do Italian API plants and CDMOs need?

Italy is the largest producer of active pharmaceutical ingredients in the European Union. Il Sole 24 Ore reported an Italian share of 26% of the EU API market, ahead of Spain at 18%, Ireland at 12% and Germany at 9%, on a 2025 sector turnover forecast of EUR 5.76 billion. Italian plants currently make 60 critical generic molecules and could take on roughly 100 more.

The producer base is concentrated and almost entirely outward-facing. Aschimfarma, the Federchimica association for active ingredients and intermediates, counted 43 member companies and 9,188 employees at the end of 2025, exporting more than 86% of production to over 90 countries.

The customers are formulators rather than pharmacies or hospitals. Generic and biosimilar companies, branded manufacturers running second-source policies, and contract manufacturers buying intermediates for their own clients. Within Italy alone, Egualia represents over 60 equivalent and biosimilar companies across nearly 40 production sites and 10,000 employees. That profile repeats in every EU market, and each one has its own procurement calendar.

What does the EU Critical Medicines Act change for Italian suppliers?

The European Commission proposed the Critical Medicines Act in March 2025 to improve the availability, supply and production of critical medicines inside the EU. It designates Strategic Projects for critical medicines and their active substances, which get easier access to funding and fast-tracked procedures, and it uses public procurement to reward resilient supply chains instead of price alone.

Council and Parliament reached a provisional agreement in May 2026. The co-legislators also cut the number of member states needed to trigger Commission-run joint procurement from nine to five, which makes cross-border tenders considerably easier to assemble. Formal adoption is expected before the end of 2026.

Aschimfarma president Pierfrancesco Morosini framed the industry position as a duty rather than an opportunity: “Ensuring the availability of critical medicines is a strategic responsibility.” Bringing the missing molecules back would take around EUR 1.5 billion of investment across EU producer countries. For plants already running to EU GMP inside the single market, the capability question is largely answered. The commercial question is not.

Why current channels cannot cover that opening

CPhI Worldwide arrives in Milan on 6 to 8 October 2026, with 2,900 or more exhibiting companies and about 62,000 attendees at Fiera Milano. Home ground is a genuine advantage. The arithmetic is less kind: three days, one stand among nearly three thousand, and a booth costing EUR 15,000 to EUR 50,000 before transport, staffing and hotels. Stand build, sample shipping and a week of senior technical staff are committed before one formulator asks a question about your Drug Master File, and none of it reaches the qualification teams that never came to Milan.

DCAT Week in New York is the other fixture that decides API and contract manufacturing business. It runs on scheduled meetings rather than stands, so the calendar fills months ahead with suppliers the buyer already knows. A company that is not on that list in January gains nothing by turning up in March.

Distributors and trading houses move a lot of Italian API volume into Asia, Latin America and the Middle East, and they sit between you and the formulator. You do not learn which customer qualified your molecule, and you cannot support a technical transfer directly. The first sign of a switch is usually that the purchase orders stop.

Field sales is the honest alternative and the costly one. A pharma-experienced export manager covering one European market runs EUR 100,000 to EUR 150,000 a year once travel is loaded in, before producing a single qualified opportunity. Five markets means five hires with the right languages and regulatory literacy. Coverage only grows when headcount grows, so a Spanish generics account and a Polish one cannot be worked by the same person in the same quarter.

Cold calling still works when a professional does it in the buyer’s language with real technical fluency. The problem is coverage. Qualifying a new supplier at a formulator pulls in procurement, quality, regulatory affairs, the qualified person and a supply-risk owner. Five roles at 200 accounts across five countries is not a call plan a mid-sized exporter can staff.

What a systematic outbound engine does instead

Targeting starts from the regulatory record rather than a purchased list. Marketing authorisation holders for the molecules you make, biosimilar developers with programmes entering scale-up, suppliers named in national tenders, and CDMOs with visible capacity gaps are all identifiable before anyone is contacted. That produces a few hundred accounts worth working, not a few thousand worth emailing.

Each account is then approached role by role. Procurement hears about dual sourcing and lead times. Regulatory affairs hears about your Drug Master File and Certificate of Suitability position. Quality hears about inspection history. Technical transfer hears about scale and analytical method support. The messages differ because the questions differ, and they go out in the recipient’s own language.

Timing comes from events that are already public: an authorisation granted, a tender published, a capacity expansion announced, a supply notification filed. Outreach arriving in the week a formulator starts hunting for a second source gets read on its merits, which is not true of the same message sent at random.

Channel	Selling days per year	Markets covered	How it scales
CPhI Milan stand	3	One venue	Fixed by who walks the hall
Field export manager	~220	1	One more hire per market
Systematic outbound	365	5+ at once	Same system, more accounts

papaverAI runs these programmes for manufacturers at $150 to $300 per qualified lead. The figure falls as the system runs, because reply data shows which roles, molecules and markets respond, and the targeting tightens around them. Fairs and field hires move the other way, since the second market costs roughly what the first one did and keeps costing it annually.

The same pattern shows up next door in Italian pharmaceutical packaging machinery, where a handful of fairs carry an industry exporting to a hundred countries, and across Italian chemicals exporters selling into the same regulated buyers.

Where to start

The Critical Medicines Act will not hand contracts to Italian plants. It makes the origin of an active substance a legitimate procurement question, and that question gets answered from whatever supplier file the buyer already keeps. Getting into that file before the rules apply is a sales task with a deadline attached, and the fair calendar does not cover it.

If you manufacture active ingredients, intermediates or finished dose in Italy and want a pipeline that runs between fairs, see how the outbound growth engine is built or tell us which export markets you are targeting. The mechanics are set out in how it works.

Sourcing from Italian pharmaceutical manufacturers? Send us your RFQ and we will map and shortlist qualified suppliers.

Frequently Asked Questions

How much does Italy export in pharmaceuticals?

Farmindustria puts 2025 exports at EUR 69.2 billion against production of EUR 74 billion, a 28.5% increase on 2024. Exports have grown 248% over ten years, well above the 148% EU average. Pharmaceuticals now make up 11.3% of Italian manufacturing exports and the sector runs an EUR 11.4 billion trade surplus.

Who actually buys from Italian API manufacturers?

Formulators rather than pharmacies: generic and biosimilar companies, branded manufacturers operating second-source policies, and contract manufacturers buying intermediates. Aschimfarma members export more than 86% of production to over 90 countries. Inside Italy, Egualia represents over 60 equivalent and biosimilar companies across nearly 40 sites, and that customer profile repeats in every EU market.

Will the EU Critical Medicines Act help Italian producers?

It creates Strategic Projects for EU manufacturing of critical medicines and their active substances, with faster procedures and better funding access, and pushes procurement to weigh supply resilience alongside price. Council and Parliament agreed a provisional text in May 2026. Italian plants hold the largest share of EU API capacity, so the opening is real but not automatic.

Is a trade fair still worth it for an Italian pharma exporter?

Yes, for demonstrations, existing customers and technical meetings that need a room. CPhI Milan on 6 to 8 October 2026 draws around 62,000 attendees to Fiera Milano. What three days cannot do is cover the other 362. A stand reaches only the formulators who walk past it, while a running outbound programme works every chosen export market year-round.

Which roles should outreach target at a pharmaceutical buyer?

Supplier qualification is a group decision. Procurement owns commercial terms, quality owns audit and inspection history, regulatory affairs owns DMF and CEP documentation, the qualified person owns release, and a supply-risk owner increasingly owns second sourcing. Reaching only one of them is why single-threaded outreach stalls at pharmaceutical accounts, however good the product is.